Novartis Says New Leukemia Drug Shows Promise

Novartis (NYSE: NVS  ) said in a press release that Tasigna, a drug currently in development that targets a form of leukemia, seems to treat the disease more effectively than the company's existing medication, Glivec -- sold as Gleevec in the United States.

The company said two-year data from its research indicates that patients who showed evidence of chronic myeloid leukemia after being treated with Glivec had undetectable levels following a switch to the new drug. Novartis characterized its findings as "statistically significant".

The company will launch a clinical trial early next year to ascertain whether patients showing positive results will be able to stop treatment entirely after a certain period of time.

Glivec will lose patent exclusivity in 2015.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2149339, ~/Articles/ArticleHandler.aspx, 7/10/2014 2:54:13 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement